Compare AstraZeneca plc (AZN) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? AstraZeneca plc trades at $166.98 (market cap $253.13B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.6. The key difference: AstraZeneca plc pays a 1.92% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none, and AstraZeneca plc is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| AZN | VCIT | |
|---|---|---|
Market Cap | $253.13B | — |
Sector | Health | Fixed Income |
52-Week High | $209.48 | $84.82 |
52-Week Low | $137.44 | $81.45 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
VCIT (Vanguard Intermediate-Term Corporate Bond ETF) trades at $81.45, down 0.44% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The fund maintains a competitive 0.03% expense ratio and approximately 5.17% SEC yield, positioning it as a cost-effective option for intermediate-duration corporate bond exposure. Recent dividend payments of $0.33-$0.34 per share demonstrate consistent income distribution to investors.
The outlook remains balanced with VCIT offering attractive yield characteristics amid moderate duration risk. Key considerations include interest rate sensitivity and corporate credit quality, with the fund providing diversification across 2,000+ investment-grade bonds. Market sentiment appears cautiously optimistic given the fund's low-cost structure and steady income profile in the current economic environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
